NeoGenomics (NEO) Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NEO shares.
View NEO analyst ratings or view top-rated stocks.

11 Wall Street research analysts have issued twelve-month target prices for NeoGenomics' stock. Their NEO share price forecasts range from $15.00 to $25.00. On average, they predict the company's share price to reach $19.55 in the next twelve months. This suggests a possible upside of 13.2% from the stock's current price.
View analysts price targets for NEO or view top-rated stocks among Wall Street analysts.

NeoGenomics' stock was trading at $9.24 at the beginning of the year. Since then, NEO stock has increased by 86.9% and is now trading at $17.27.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our NEO earnings forecast.

NeoGenomics, Inc. (NASDAQ:NEO) posted its quarterly earnings results on Thursday, November, 4th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. The medical research company earned $121.30 million during the quarter, compared to analyst estimates of $125.09 million. NeoGenomics had a negative net margin of 23.72% and a negative trailing twelve-month return on equity of 7.34%. The firm's revenue was down 3.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.04 EPS.

ETFs with the largest weight of NeoGenomics (NASDAQ:NEO) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Services ETF (XHS), Invesco DWA Healthcare Momentum ETF (PTH), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), WisdomTree BioRevolution Fund (WDNA), Principal Healthcare Innovators ETF (BTEC), Vanguard S&P Small-Cap 600 Value ETF (VIOV).SPDR S&P 600 Small CapValue ETF (SLYV).

NeoGenomics updated its FY 2023 earnings guidance on Friday, April, 14th. The company provided earnings per share guidance of -$0.38--$0.32 for the period, compared to the consensus EPS estimate of -$0.44. The company issued revenue guidance of $545.00 million-$555.00 million, compared to the consensus revenue estimate of $549.97 million.

116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

NeoGenomics' stock is owned by a number of retail and institutional investors. Top institutional investors include Brown Advisory Inc. (5.17%), State Street Corp (3.83%), Greenhouse Funds LLLP (2.30%), First Light Asset Management LLC (2.12%), Dimensional Fund Advisors LP (2.11%) and Geode Capital Management LLC (1.97%). Insiders that own company stock include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Mark Mallon, Oort Douglas M Van, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends.

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NEO stock can currently be purchased for approximately $17.27.

NeoGenomics (NASDAQ:NEO) has a market capitalization of $2.20 billion and generates $509.73 million in revenue each year. The medical research company earns $-144,250,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

The company employs 2,100 workers across the globe.

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The official website for the company is www.neogenomics.com. The medical research company can be reached via phone at (239) 768-0600, via email at sjones@neogenomics.com, or via fax at 239-690-4237.